Market Overview

From Biogen Call: Eloctate Could Be Facing Potential Approval Delay

Share:
Related BIIB
3 ETFs To Watch Out For On Biotech Earnings
19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug

Posted-In: News FDA

 

Related Articles (BIIB)

View Comments and Join the Discussion!